Month: June 2022

Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients

06/27/2022

Excerpt from the Press Release: BOSTON & SEATTLE & EMERYVILLE, Calif.–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, and Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation, wholly-owned gene editing tools, today announced a partnership to enable Affini-T’s next generation ex vivo…

Read More

BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies

06/27/2022

Excerpt from the Press Release: SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,357,463: titled, “Target Site Selection, Entry and Update With Automatic Remote Image…

Read More

ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC

06/24/2022

Excerpt from the Press Release: FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the submission of its Vitrargus Phase II study to the Australian Bellberry Human Research Ethics Committee (HREC). If received,…

Read More

Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC

06/24/2022

GB1211, Galecto’s galectin-3 inhibitor, has shown potent anti-tumor effects and increased efficacy of checkpoint inhibition in pre-clinical models Excerpt from the Press Release: BOSTON, June 16, 2022 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that the first…

Read More

SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs

06/24/2022

Pre-Clinical Research Could Lead to Rapid Development of Dopamine-Producing Neurons; Part of Company’s NIH-Funded Program Seeking Scalable Cell Replacement Therapy Approaches for Parkinson’s Disease Use of Non-Viral, Self-Amplifying RNA Enhanced and Lengthened Transcription Factor Expression, Driving the Signaling Required for Dopamine-Producing Neuron Development Findings Presented at 2022 International Society for Stem Cell Research Annual Meeting…

Read More

Lassen Therapeutics Presents New Preclinical Data on IL-11 Receptor-blocking as a Novel Therapeutic Approach for Skin Fibrosis at Keystone Symposia Conference

06/23/2022

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today presented new preclinical data on LASN01, a monoclonal antibody targeting IL-11 receptor (IL-11R), in preclinical models of skin fibrosis at the Keystone Symposia Conference on Tissue Fibrosis and Repair:…

Read More

Blue Earth Therapeutics Announces Promising Results of Preclinical Biodistribution and Efficacy Evaluation of 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

06/23/2022

− 177Lutetium-labelled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical – − 177Lu‑rhPSMA-10.1 demonstrated favorable tumor:kidney ratio and statistically significant tumor growth suppression in preclinical studies − − Phase 1/2 clinical trial of 177Lu-rhPSMA-10.1 in men with metastatic castrate‑resistant prostate cancer recently cleared to proceed in United…

Read More

Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

06/23/2022

– Study evaluates pre-administration of cold antibody prior to administration of imaging agent – Imaging shows favorable gain in tumor lesion uptake versus normal tissue when cold antibody is pre-administered – Data presented at the SNMMI 2022 Annual Meeting Excerpt from the Press Release: HAMILTON, ON and BOSTON, June 14, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc.…

Read More

Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413

06/22/2022

KT-333 is a first-in-class heterobifunctional degrader of the transcriptional regulator STAT3 in development for T cell malignancies and solid tumors KT-413 is a first-in-class degrader of IRAK4 and the IMiD substrates Ikaros and Aiolos in development for MYD88-mutant B cell lymphomas  Initial safety and proof-of-mechanism clinical data for both programs to be shared in second…

Read More

Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

06/22/2022

Investigational New Drug Application Submitted by Omega Represents the First Epigenomic Controller in a New Class of Programmable mRNA Therapeutics Excerpt from the Press Release: CAMBRIDGE, Mass., June 15, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug…

Read More